» Articles » PMID: 15141303

Expression of the Stp1 LMW-PTP and Inhibition of Protein CK2 Display a Cooperative Effect on Immunophilin Fpr3 Tyrosine Phosphorylation and Saccharomyces Cerevisiae Growth

Overview
Publisher Springer
Specialty Biology
Date 2004 May 14
PMID 15141303
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Although the yeast genome does not encode bona fide protein tyrosine kinases, tyrosine-phosphorylated proteins are numerous, suggesting that besides dual-specificity kinases, some Ser/Thr kinases are also committed to tyrosine phosphorylation in Saccharomyces cerevisiae. Here we show that blockage of the highly pleiotropic Ser/Thr kinase CK2 with a specific inhibitor synergizes with the overexpression of Stp1 low-molecular-weight protein tyrosine phosphatase (PTP) in inducing a severe growth-defective phenotype, consistent with a prominent role for CK2 in tyrosine phosphorylation in yeast. We also present in vivo evidence that immunophilin Fpr3, the only tyrosine-phosphorylated CK2 substrate recognized so far, interacts with and is dephosphorylated by Spt1. These data disclose a functional correlation between CK2 and LMW-PTPs, and suggest that reversible phosphorylation of Fpr3 plays a role in the regulation of growth rate and budding in S. cerevisiae.

Citing Articles

Lawsonia intracellularis LI0666 is a new EPIYA effector exported by the Yersinia enterocolitica type III secretion system.

Chen C, Dai Y, Yang Y, Zhu Z, Zhang Q, An X Vet Res. 2022; 53(1):39.

PMID: 35659762 PMC: 9167531. DOI: 10.1186/s13567-022-01054-9.


Identification and comparative analysis of sixteen fungal peptidyl-prolyl cis/trans isomerase repertoires.

Pemberton T BMC Genomics. 2006; 7:244.

PMID: 16995943 PMC: 1618848. DOI: 10.1186/1471-2164-7-244.


Solution structure of a low-molecular-weight protein tyrosine phosphatase from Bacillus subtilis.

Xu H, Xia B, Jin C J Bacteriol. 2006; 188(4):1509-17.

PMID: 16452434 PMC: 1367216. DOI: 10.1128/JB.188.4.1509-1517.2006.


Development and exploitation of CK2 inhibitors.

Sarno S, Ruzzene M, Frascella P, Pagano M, Meggio F, Zambon A Mol Cell Biochem. 2005; 274(1-2):69-76.

PMID: 16335530 DOI: 10.1007/s11010-005-3079-z.

References
1.
Galie N, Hoeper M, Humbert M, Torbicki A, Vachiery J, Barbera J . Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the.... Eur Heart J. 2009; 30(20):2493-537. DOI: 10.1093/eurheartj/ehp297. View

2.
Simonneau G, Robbins I, Beghetti M, Channick R, Delcroix M, Denton C . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S43-S54. DOI: 10.1016/j.jacc.2009.04.012. View

3.
Johnson S, Granton J, Mehta S . Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest. 2006; 130(2):545-52. DOI: 10.1378/chest.130.2.545. View

4.
Agarwal P, Wolfsohn A, Matzinger F, Seely J, Peterson R, Dennie C . In situ central pulmonary artery thrombosis in primary pulmonary hypertension. Acta Radiol. 2005; 46(7):696-700. DOI: 10.1080/02841850500215501. View

5.
Tournier A, Wahl D, Chaouat A, Max J, Regnault V, Lecompte T . Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. Thromb Res. 2010; 126(6):e418-22. DOI: 10.1016/j.thromres.2010.08.020. View